CEL-SCI Corporation (NYSE:CVM) CEO Geert Kersten sat down with Proactive Investors at the ThinkEquity Conference in New York. The Virginia-based biotech treats patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with its drug Multikine before they receive surgery, radiation and/or chemotherapy.
CelSci updates Phase 3 clinical trial of Advanced Head and Neck Cancer treatment
Quick facts: CEL-SCI Corporation
Price: 12.14 USD
Market Cap: $457.63 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE